# RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.

> **NCT02176122** · PHASE4 · TERMINATED · sponsor: **The University of Queensland** · enrollment: 391 (actual)

## Conditions studied

- Bloodstream Infections

## Interventions

- **DRUG:** Meropenem
- **DRUG:** Piperacillin-tazobactam combination product

## Key facts

- **NCT ID:** NCT02176122
- **Lead sponsor:** The University of Queensland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2017-07-07
- **Final completion:** 2017-08-07
- **Target enrollment:** 391 (ACTUAL)
- **Why stopped:** Secondary to third interim analysis by the study DSMB.
- **Last updated:** 2017-11-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02176122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02176122, "RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02176122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*